Last reviewed · How we verify
Rabeprazole 40 mg (rabeprazole-40-mg)
Rabeprazole 40 mg (generic name: rabeprazole-40-mg) is a Proton Pump Inhibitor drug developed by Pfizer. It is currently FDA-approved for Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis, Pathological Hypersecretory Conditions.
Rabeprazole 40 mg is a small molecule used to evaluate its effects on the pharmacokinetics of other medications, such as nirogacestat, in clinical trials. It has been studied in conditions including gastroesophageal reflux disease and calcium metabolism disorders.
At a glance
| Generic name | rabeprazole-40-mg |
|---|---|
| Sponsor | Pfizer |
| Drug class | Proton Pump Inhibitor |
| Target | H+/K+ ATPase |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Approved indications
- Gastroesophageal Reflux Disease (GERD)
- Erosive Esophagitis
- Pathological Hypersecretory Conditions
- Zollinger-Ellison Syndrome
- Erosive Esophagitis in Pediatric Patients 1 to 11 Years Old
- Gastroesophageal Reflux Disease (GERD) in Pediatric Patients 1 to 11 Years Old
Common side effects
Drug interactions
- Atazanavir
- Clopidogrel
- Ketoconazole
- Erythromycin
- Warfarin
- Digoxin
- Methotrexate
- Tacrolimus
- Amoxicillin
- Cyclosporine
- Iron
- Calcium
Key clinical trials
- A Study to Learn How a Medicine That Reduces Stomach Acid Affects the Level of Sisunatovir in the Blood of Healthy Adults. (PHASE1)
- HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI (PHASE1)
- Fruquintinib Food Effect and Proton Pump Inhibitor Study (PHASE1)
- Surufatinib DDI With a PPI and a CYP3A Inducer (PHASE1)
- A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors (PHASE1)
- A Study of E3810 for Japanese Subjects With Functional Dyspepsia (SAMURAI Study: Suppression of Acid Milieu With Rabeprazole Improving Functional Dyspepsia ) (Study E3810-J081-204) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rabeprazole 40 mg CI brief — competitive landscape report
- Rabeprazole 40 mg updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Rabeprazole 40 mg
What is Rabeprazole 40 mg?
What is Rabeprazole 40 mg used for?
Who makes Rabeprazole 40 mg?
What is the generic name of Rabeprazole 40 mg?
What drug class is Rabeprazole 40 mg in?
What development phase is Rabeprazole 40 mg in?
What does Rabeprazole 40 mg target?
Related
- Drug class: All Proton Pump Inhibitor drugs
- Target: All drugs targeting H+/K+ ATPase
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Gastroenterology
- Indication: Drugs for Gastroesophageal Reflux Disease (GERD)
- Indication: Drugs for Erosive Esophagitis
- Indication: Drugs for Pathological Hypersecretory Conditions
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing